Cabozantinib Improves PFS in Radioiodine-Refractory Differentiated Thyroid Cancer
Cabozantinib prolongs progression-free survival in patients with previously treated radioiodine-refractory differentiated thyroid cancer, a phase 3 trial suggests.
Endocrine Cancer
Proton FLASH Radiotherapy Deemed Feasible, Comparable to Conventional Dose Rate Radiotherapy
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
Treatment Changes May Have Reduced Rates of Invasive Breast Cancer in Childhood Cancer Survivors
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Active Surveillance Feasible for Low-Risk Thyroid Cancer
Active surveillance may be a viable management strategy for most diagnosed thyroid cancers, according to researchers.
Donafenib May Be Alternative for Progressive, Advanced RAIR-DTC
Donafenib demonstrated efficacy in patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
177Lutetium-Octeotrate May Be Practice-Changing for Advanced Pancreatic Neuroendocrine Tumors
177Lutetium-octreotate can improve progression-free survival vs sunitinib in patients with progressive pancreatic neuroendocrine tumors.
Chemotherapy Doublets Remain Standard Care for Advanced Digestive Neuroendocrine Carcinoma
Etoposide plus cisplatin and irinotecan plus cisplatin remain the standard first-line chemotherapy options for advanced digestive neuroendocrine carcinoma, according to researchers.
Men Have Higher Risk of Cancer; Demographic and Lifestyle Factors Don’t Explain It
Men tend to have a higher risk of cancer than women, and factors such as smoking, alcohol use, and diet do not appear to explain this disparity.
Thyroid Cancer Often Detected in Asymptomatic Patients
Many thyroid cancers are discovered in patients who undergo surgery without thyroid-referable symptoms, an international study suggests.
Blood Type Linked to Outcomes of Immune Checkpoint Inhibitor Therapy in Metastatic Cancer
Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...